Kezar Life Sciences, Inc. (NASDAQ: KZR)

Kezar Life Sciences, Inc. (KZR), a clinical-stage biotechnology company, is dedicated to developing novel small molecule therapeutics that address unmet needs in immune-mediated diseases and cancer. The company's operations span various regions, with its headquarters in South San Francisco, California.

Kezar Life Sciences' primary business activities revolve around the research, development, and commercialization of innovative therapeutic solutions. Its product candidates are designed to target unmet medical needs in immune-mediated diseases and cancer.

The company's revenue is generated through the development and commercialization of its product candidates. Its lead product candidate, zetomipzomib, is a selective immunoproteasome inhibitor that has successfully completed Phase 1a testing in healthy volunteers and a Phase 1b/2a clinical trial in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). Another significant product candidate is KZR-261, a first-in-class protein secretion inhibitor that has demonstrated broad anti-tumor activity in preclinical models of both solid and hematologic malignancies.

Within the industry, Kezar Life Sciences holds a unique position as a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases and cancer. Its key competitors include established pharmaceutical and biotechnology companies such as Aurinia Pharmaceuticals, GlaxoSmithKline, and Novartis, among others. The company's competitive advantages lie in its strong intellectual property position, with patent coverage for zetomipzomib extending to at least 2034, and its established collaborations and license agreements with Onyx Therapeutics, Inc. and Everest Medicines II (HK) Limited.

Kezar Life Sciences' customers include patients with immune-mediated diseases and cancer, as well as healthcare providers and payers who provide access to these treatments.

The company's product portfolio includes the following brands and/or trade names: zetomipzomib and KZR-261.